Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Nanobiotix ( (NBTX) ) has provided an update.
On December 1, 2025, Nanobiotix S.A. announced the disclosure of transactions by persons discharging managerial responsibilities in compliance with EU Market Abuse Regulation. This announcement included details of a significant transaction on November 26, 2025, where shares were sold to repay bank loans used for financing stock options. This transaction allowed the company to eliminate the pledge on the remaining shares, potentially improving its financial flexibility and stakeholder confidence.
The most recent analyst rating on (NBTX) stock is a Hold with a $22.00 price target. To see the full list of analyst forecasts on Nanobiotix stock, see the NBTX Stock Forecast page.
Spark’s Take on NBTX Stock
According to Spark, TipRanks’ AI Analyst, NBTX is a Neutral.
Nanobiotix’s overall stock score is primarily impacted by its poor financial performance, with significant operational losses and financial instability. While technical analysis shows some positive momentum, the negative valuation metrics due to lack of profitability further weigh down the score.
To see Spark’s full report on NBTX stock, click here.
More about Nanobiotix
Nanobiotix S.A. operates in the biotechnology industry, focusing on the development of innovative nanomedicine products for cancer treatment. The company is known for its pioneering work in nanotechnology-based therapies, particularly in enhancing the efficacy of radiotherapy for cancer patients.
Average Trading Volume: 98,543
Technical Sentiment Signal: Buy
Current Market Cap: $965.6M
For a thorough assessment of NBTX stock, go to TipRanks’ Stock Analysis page.